术前化疗期间肌肉量流失预示结直肠癌肝转移患者生存不良
本研究回顾性分析169例接受术前化疗及治愈性肝切除术的结直肠癌肝转移患者,按骨骼肌指数和体重变化分组。
要点
- 术前化疗期间肌肉量流失≥7%与肝切除后无复发生存期缩短独立相关。
- 骨骼肌指数绝对值(化疗前或后)与无复发生存或总生存无关。
- 体重变化未显示与生存的独立关联,肌肉量变化更具预后价值。
核心结论
- 术前化疗期间肌肉量显著流失(≥7%)而非体重下降,与结直肠癌肝转移患者肝切除后无复发生存期差独立相关。
研究设计与样本
- 回顾性分析2009-2013年连续169例接受术前化疗及治愈性肝切除术的结直肠癌肝转移患者,中位随访47个月。
主要发现
- 化疗前或后骨骼肌指数绝对值与无复发生存或总生存均无关。
临床怎么用
- 术前化疗期间应关注肌肉量变化,可考虑营养与运动干预以维持肌肉量,可能改善肝切除后预后。
局限性
- 回顾性单中心设计,样本量有限,肌肉量流失与生存关联的机制未明确,需前瞻性研究验证干预价值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The survival impact of specific body composition changes during preoperative chemotherapy in patients with colorectal liver metastases undergoing curative-intent surgery remains unclear. This study aimed to determine the impact of changes in body weight and muscle mass during preoperative chemotherapy on survival after hepatectomy in patients with colorectal liver metastases. METHODS: Consecutive patients with colorectal liver metastases undergoing preoperative chemotherapy and curative hepatectomy during 2009-2013 were retrospectively analyzed. Recurrence-free and overall survival were examined according to body compositions, including muscle mass, as measured by skeletal muscle index (area of muscle [cm2]/square of height [m2]), and body weight before and after preoperative chemotherapy. RESULTS: The median follow-up duration in overall 169 patients was 47 months. Skeletal muscle index and body weight changed significantly during chemotherapy (skeletal muscle index: -0.52 cm2/m2, P = .03; body weight: +1.1 kg, P = .002). Patients with major muscle mass loss (≥7%) had significantly shorter median RFS than patients with no or minor muscle mass loss (<7%) (9.6 months vs 15.9 months; P = .02). Although major muscle mass loss was associated with poor outcome, skeletal muscle index before or after preoperative chemotherapy was not associated with recurrence-free or overall survival. On multivariate analysis, major muscle mass loss was independently associated with poorer recurrence-free survival (hazard ratio, 1.76; P = .045). CONCLUSION: Major loss of muscle mass but not body weight loss during preoperative chemotherapy is significantly associated with poor recurrence-free survival after hepatectomy in patients with colorectal liver metastases. The mechanisms mediating this association may inform future trials on maintaining muscle mass with dedicated nutrition and exercise programs to improve outcomes.
引用
- Okuno M, Goumard C, Kopetz S, et al. Loss of muscle mass during preoperative chemotherapy as a prognosticator for poor survival in patients with colorectal liver metastases. Surgery. 2018. PMID: 30197278. doi:10.1016/j.surg.2018.07.031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。